Loss-of-function of alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein leads to a phenotype called alternative lengthening of telomeres (ALT) in some tumors. High-grade astrocytomas comprise a heterogeneous group of central nervous system tumors. We examined a large cohort of adult (91) and pediatric (n ¼ 88) high-grade astrocytomas as well as lower grade forms (n ¼ 35) for immunohistochemical loss of ATRX protein expression and the presence of ALT using telomere-specific fluorescence in situ hybridization, with further correlation to other known genetic alterations. We found that in pediatric high-grade astrocytomas, 29.6% of tumors were positive for ALT and 24.5% were immunonegative for the ATRX protein, these two alterations being highly associated with one another (Po0.0001). In adult high-grade astrocytomas, 26.4% of tumors were similarly positive for ALT, including 80% of ATRX protein immunonegative cases (Po0.0001). Similar frequencies were found in 11 adult low-grade astrocytomas, whereas all 24 pilocytic astrocytomas were negative for ALT. We did not find any significant correlations between isocitrate dehydrogenase status and either ALT positivity or ATRX protein expression in our adult high-grade astrocytomas. In both cohorts, however, the ALT positive high-grade astrocytomas showed more frequent amplification of the platelet-derived growth factor receptor alpha gene (PDGFRA; 45% and 50%, respectively) than the ALT negative counterparts (18% and 26%; P ¼ 0.03 for each). In summary, our data show that the ALT and ATRX protein alterations are common in both pediatric and adult highgrade astrocytomas, often with associated PDGFRA gene amplification. Modern Pathology (2013Pathology ( ) 26, 1425Pathology ( -1432 doi:10.1038/modpathol.2013 published online 14 June 2013 Keywords: alternative lengthening of telomeres; ATRX; astrocytoma; FISH; glioblastoma; IDH1; PDGFRA Approximately 22 000 new cases of brain and central nervous system tumors are diagnosed each year in the United States, and 3000 of those are in children. Pediatric gliomas comprise a clinically, histologically and molecularly heterogeneous group
of central nervous system tumors. 1 In addition, gene expression signatures indicate differences between adult and pediatric cases, [1] [2] [3] although they are histologically indistinguishable and uniformly classified by the current WHO classification for central nervous system tumors. 4 Alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein belongs to the SWI2/ sucrose non-fermenting 2 family of chromatin remodeling proteins. ATRX and death-domain associated protein (DAXX) form a complex that interacts with histone protein H3.3 to assemble chromatin and telomeres. 5, 6 Mutations that inactivate these genes are common in human pancreatic neuroendocrine tumors and central nervous system tumors. 3, [7] [8] [9] Loss of ATRX or DAXX function impairs the heterochromatic state of the telomeres, perhaps because of reduced incorporation of chromatin onto H3.3 histones. 8 This leads to telomere destabilization, which results in a telomerase-independent telomeremaintenance mechanism called alternative lengthening of telomeres (ALT). ALT can lead to immortalization of cells and carcinogenesis 10, 11 and is not seen in normal cells. 12 Although the majority of authors have found close relationships between ATRX loss and ALT in diffuse gliomas, 7, 8, 13 at least one study found no statistically significant association. 14 A majority of diffuse low-grade and anaplastic adult astrocytomas, as well as secondary forms of glioblastoma, harbor mutations in the genes encoding isocitrate dehydrogenase IDH1 and IDH2. 14 IDH mutations and ATRX gene alterations often appear together in these astrocytomas. 14 In addition, highgrade astrocytomas that lack ATRX expression and are ALT-positive often have mutations in the IDH genes. 13 However, in contrast to adult central nervous system tumors, IDH mutations are exceptionally rare in pediatric high-grade astrocytomas. Amplification of the platelet-derived growth factor receptor alpha (PDGFRA) gene occurs in significant subsets of pediatric and adult high-grade astrocytomas. 2, [15] [16] [17] [18] [19] [20] As ALT and ATRX mutations are also common in high-grade astrocytomas, particularly in pediatric and young adult populations, we wanted to investigate the association of PDGFRA amplification with alterations in ALT/ATRX in adult and pediatric gliomas. To date, the correlation between ALT and ATRX remains somewhat uncertain, and potential associations between PDGFRA and ALT/ATRX status have not been investigated. Our findings suggest a significant association between ALT positivity and loss of ATRX in both adult and pediatric high-grade astrocytomas and a correlation between ALT and PDGFRA status. It was also prevalent in adult low-grade astrocytomas, as recently confirmed by another group. 21 We also found a correlation between ALT and PDGFRA status. 
Materials and methods

Cohort
Immunohistochemical Analysis of Control Pancreatic Neuroendocrine and Central Nervous System Tumors Samples
ATRX immunolabeling was performed on formalinfixed, paraffin-embedded sections as described previously. 7 Briefly, heat-induced antigen retrieval was performed in a steamer using CC1 buffer (catalog# H-3300, Vector Laboratories) for 30 min. Endogenous peroxidase was blocked (catalog# S2003, Dako) and serial sections were incubated for 1 h at room temperature in anti-ATRX primary antibody (1:300; catalog# HPA001906, SigmaAldrich, lot R00473). Following washing, sections were incubated for 30 min with horseradish peroxidase-labeled secondary antibody (catalog# PV6119, Leica Microsystems) followed by detection with 3, 3 0 diaminobenzidine (SigmaAldrich), counterstaining with Harris hematoxylin, rehydration and mounting. Only nuclear labeling was evaluated. One pathologist assessed the immunolabeled pancreatic neuroendocrine tumors specimens (MA).
The study cohort consisted of 88 pediatric highgrade astrocytomas, 24 pediatric pilocytic astrocytomas, 91 adult high-grade astrocytomas and 11 adult low-grade WHO grade II astrocytomas. Highgrade astrocytomas included those diagnosed as WHO grade IV glioblastomas and WHO grade III anaplastic astrocytomas. Owing to the limited availability of tissue, ALT was first performed on all available cases (88 pediatric high-grade astrocytomas, 91 adult high-grade astrocytomas, 11 adult low-grade astrocytomas and 24 pilocytic astrocytoma) and then, ATRX was performed on as many remaining cases as possible (77/88 pediatric high-grade astrocytomas and 74/91 of adult highgrade astrocytomas, 11 adult low-grade astrocytomas, 24 pediatric pilocytic; Tables 1 and 2 ). Internal positive controls for ATRX included endothelial cells within intratumoral vessels and non-neoplastic neurons. Both cell types demonstrated strong nuclear immunolabeling.
Telomere-Specific and PDGFRA FISH and Microscopy
The commercially available Telomere FISH Kit/Cy3 (DAKO, catalog code K5326) was used according to the manufacturer's instructions. Briefly, after pre-treatment with formaldehyde and a solution containing proteinase K for 10 min, the sample DNA was denatured at 80 1C for 4 min under a coverslip in the presence of the Cy3-conjugated probe. Hybridization (1 h at room temperature) was followed by two washes with solutions provided in the kit. Afterward, sections were mounted in antifade reagent containing 4 0 , 6-diamidino-2-phenylindole as counterstain.
PDGFRA FISH was performed and scored as previously described. 20 Briefly, unstained slides were deparaffinized by heating them at 70 1C for 15 min, and then placed in two 10-min washes with Citrisolv, three 3-min washes in isopropanol, and a 20-min wash in 0.2 N HCL. The slides were rinsed in running water for 10 min. DNA target retrieval was achieved by immersing the slides in citrate buffer for 30 min at 80 1C. Slides were rinsed in running water for 10 min. For tissue digestion, the slides were placed in pepsin (P-7012, Sigma-Aldrich; 2.5 mg/ml in water) for 25 min at 37 1C followed by a 10-min rinse under running water. The slides were then placed in 2 Â SSC for 5 min. A rhodamine-labeled PDGFRA probe was diluted 1:10 in DenHyb (Insitus Biotechnologies, Albuquerque, NM, USA), and the CEP 4 reference probe (Abbott Molecular) was diluted 1:25 in DenHyb. The combined probes were applied to the tissue and co-denatured with the target DNA at 88 1C for 12 min. The slides were then transferred to a humidified slide moat and incubated overnight at 37 1C. The next day, slides were placed in 50% formamide/50% 2 Â SSC for 5 min to remove the coverslips followed by two 10-min washes in 2 Â SSC. Depending on the surface area of the tissue, 10-20 ml of 4 0 , 6-diamidino-2-phenylindole in Fluorguard (Insitus) was placed on the section followed by a coverslip. Signals were observed with an Olympus BX 41 fluorescence microscope.
The ALT FISH and immunolabeled slides were independently assessed and scored by three authors (MA, RM and AP). Large, ultra-bright telomere repeat DNA aggregates defined ALT-positive cell populations as opposed to the small delicate signals derived from normal individual telomeres. ALTpositive cases were identified by large, very bright telomere FISH signals in Z1% of the tumor cells. A tumor was considered ALT negative if at least 500 consecutive cells lacked large ultrabright telomeric signals. In all cases, areas exhibiting necrosis were excluded from analysis.
Statistical Analysis
Correlations between categorical variables were analyzed with w 2 or Fisher's exact tests. Overall survival was examined by Cox or Kaplan-Meier tests. P-values o0.05 were considered statistically significant. All statistical analyses were performed by one author (JC). 
Results
Validation of Pancreatic Neuroendocrine Tumors Immunocytochemistry and Telomere-Specific FISH
We first examined 30 sporadic non-functional pancreatic neuroendocrine tumors for technical validation and to provide appropriate positive and negative controls for subsequent experiments. In all, 10 of the 30 pancreatic neuroendocrine tumors (33.3%) were ALT positive and had ATRX or DAXX loss according to immunohistochemistry (Figure 1 ).
Association of ALT and ATRX Loss in Pediatric High-Grade Astrocytomas
A total of 26 of 88 pediatric high-grade astrocytomas (29.6%) were ALT positive ( Figure 2a , Table 1 ). In contrast, none of the 24 pilocytic astrocytomas were ALT positive. We examined 77 of the 88 tumors for ATRX staining. Although 24.5% (19/77) of pediatric high-grade astrocytomas showed loss of ATRX staining ( Table 2 , Figure 2b ), expression was retained in all 24 pilocytic astrocytomas. Among 19 high-grade astrocytomas in which ATRX was lost, 16 (84.2%) were ALT positive (Table 3) . Thus, loss of ATRX staining was significantly associated with ALT in pediatric high-grade astrocytomas (Po0.0001). Further stratification of high-grade tumors into WHO grade III vs IV showed significant associations between ALT positivity and ATRX loss within pediatric anaplastic astrocytoma and glioblastomas subset (Table 4) .
Association of ALT and ATRX Loss in Adult High-Grade Astrocytomas
Telomere-specific FISH analysis in adult high-grade astrocytomas identified ALT positivity in 24 of 91 cases (26.4%; Table 1 ). Similar results were observed in adult low-grade diffuse astrocytomas in which 3 of 11 (27.3%) were ALT positive. We examined 74 of the 91 tumors for ATRX. ATRX staining was absent in 15 of 74 (20.3%) high-grade astrocytomas and 1 of 11 (9.1%) low-grade WHO grade II astrocytomas (Table 2 ). Among 15 highgrade astrocytomas in which ATRX was lost, 12 (80%) were ALT positive (Table 3 ; Po0.0001). ATRX loss was not associated with ALT in low-grade adult astrocytomas, which may reflect the small sample size and the rarity of ATRX immunonegativity.
The associations between ALT positivity and ATRX loss in high-grade astrocytomas remained statistically significant with sub-stratification into adult anaplastic astrocytoma and glioblastoma subsets (Po0.0001; Table 4 ). (Table 5) . Our data suggested a trend between IDH1 R132H immunopositivity and either ALT positivity or ATRX loss, although these correlations did not reach statistical significance (Table 5 ; P ¼ 0.116 and P ¼ 0.115, respectively).
Associations Between PDGFRA Amplification and ALT/ATRX Status in Pediatric and Adult High-Grade Astrocytomas Table 6 summarizes the relationship between ALT and PDGFRA amplification in both adult and pediatric high-grade astrocytomas. In adult highgrade astrocytomas, 50% (9/18) of ALT-positive cases harbored PDGFRA amplification, which was significantly higher than the 26% (14/54) amplification rate seen in ALT-negative tumors (P ¼ 0.031). A similar statistically significant association was found in pediatric high-grade astrocytomas, in which 45% (9/20) of amplified tumors were ALTpositive and 18% (7/40) of ALT-negative tumors had PDGFRA amplification (P ¼ 0.032). ATRX loss was also more common in PDGFRA-amplified adult and pediatric high-grade astrocytomas. However, these associations did not reach statistical significance, yielding P-values of 0.181 and 0.195, respectively, ( Table 7) .
Survival Analysis
Survival data in reference to PDGFRA status have been reported in part previously. 20 Follow-up data until time of death was obtained in 83 (91%) adult and 55 (66%) pediatric high-grade astrocytoma patients, with median follow-up times of 474 and 419 days, respectively. Median age in years in adult and pediatric high-grade astrocytoma patients with ALT positive/ATRX loss phenotype was 40.7 and 10.3, respectively. Median age in years for highgrade astrocytomas of ALT negative/ATRX intact phenotype was 46.7 in adult and 6.3 in pediatric.
No statistically significant associations were found between the ALT or ATRX status (alone or combined) and overall survival in either age group. Similarly, combinations of ALT status with IDH1 or PDGFRA data were not statistically associated with overall survival times in our cohort.
Discussion
Recent studies have shown conflicting data regarding the association between ATRX loss and ALT status in glioblastomas. 13, 14 Our data suggest that the ALT phenotype is highly associated with ATRX loss in high-grade astrocytomas of both age groups (Po0.0001), supporting the model in which loss of ATRX function impairs the heterochromatic state of telomeres, perhaps because of reduced levels of histone H3.3 incorporation; this subsequently leads to telomere destabilization and increased homologous recombination, thus facilitating the development of ALT. 8, 22 Abnormally long telomeres are known to be associated with cell immortality and cancer. 10, 11, 23 As such, telomeretargeted therapies should be studied further for their potential benefits in patients with ALT-positive tumors. Although telomerase inhibition may result in adverse toxicity to bone marrow or other progenitor cell populations, 24 this strategy may nonetheless benefit many cancer patients. Telomerase knockdown strategies or viruses that target telomerase could also limit the survival of cancer cells that show telomere dysfunction, including those with ALT. A recent study proposed six biological classification subgroups of glioblastoma based on global DNA methylation patterns. 3 Most patients whose tumors were characterized by the protein complex of G34 or K27 mutant histone H3.3 and ATRX clustered in the adolescent and young adult populations. Although we did not test the H3.3 mutation status in our cohort, we did not find ATRX losses to be restricted to young adults (the range of age between 20 and 79 with a median of 40.7 years) or adolescents (the range age for the pediatric group was between 5 and 17 with a median of 10.3 years).
In contrast to the study by Nguyen et al, 13 we did not find a significant improvement in survival for ALT-positive high-grade astrocytoma patients in our cohort.
Amplification of the PDGFRA gene is also present in a significant subset of pediatric and adult highgrade astrocytomas. 2, [15] [16] [17] [18] [19] [20] Of interest, our study identified a significant association between PDGFRA amplification and ALT positivity in both adult and pediatric high-grade astrocytomas (P ¼ 0.03). The biological explanation for this association is not clear, but suggests that perhaps inhibition of the PDGFRA signaling pathway may be beneficial in this subgroup of patients. Further studies exploring this association are therefore warranted.
In summary, the ALT phenotype and ATRX losses identify significant biological subsets of high-grade astrocytoma in both adult and pediatric patients. Our results show that telomere-specific FISH and ATRX staining are reliable detection assays in formalin-fixed, paraffin-embedded tissue with 80-84% concordance. There are a number of potential explanations for non-concordant cases. For example, some missense ATRX mutations would not be detected by routine immunohistochemistry. ALT may also occur because of mutations of other genes, such as DAXX, although this appears to be rare in gliomas. We also used strict criteria in scoring the ATRX loss, which we defined as being 100% absent in tumor nuclei. This approach is more likely to be feasible and reproducible, allowing establishment of ATRX loss as a clinical biomarker. Thus, ATRX IHC alone can underestimate mutation status and ALT incidence. In terms of deciding which assay to use in a clinical or routine pathology setting, immunohistochemistry is simpler, cheaper and more readily available. Nevertheless, given that ALT is the end product determining aberrant telomere maintenance, the FISH assay may be of greater biological relevance. Finally, our study found potential interactions between ALT/ATRX and other genetic alterations such as PDGFRA amplification, which should be explored further in the development of individualized treatment strategies. 
